Drug Trial Radar · NCT06445959
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Aug 29, 2024
Primary completion
Jun 30, 2027
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rigel Pharmaceuticals,Inc.
- First posted
- Jun 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Conditions
- Mutant IDH1 Inhibitor Olutasidenib
Interventions
OlutasidenibDrug
Given by PO
VenetoclaxDrug
Given by PO
DecitabineDrug
Given by IV
Decitabine/cedazuridineDrug
Given by PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Recruiting
The University of Kansas Medical Center
Westwood, Kansas · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Roswell Park
Buffalo, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.